美股A股
StockGist
Back
10-Q2026-04-30· glm-5

PCRX · Pacira BioSciences, Inc.

0001628280-26-028871

SEC filing

Summary

Topline growth and a tripling of operating income were offset by a decline in net income, as the prior-year period benefited from non-recurring gains. The company maintained strong margins and free cash flow generation despite pricing headwinds and tariff uncertainty.

Key takeaways

Full analysis

Product Portfolio Drives Topline Amidst Pricing Headwinds

Operating Leverage Emerges Despite Prior-Year Comparisons

The company demonstrated significant operating leverage, with operating income tripling to $6.9M compared to $2.0M in Q1 FY2025. This 247% improvement reflects the scalability of the business model as revenue grew faster than operating costs. Gross profit increased 4.7% to $141.0M, maintaining a strong gross margin of 79.5%. However, the bottom line told a different story. Net income fell 39% to $2.9M, or $0.07 per diluted share, down from $4.8M, or $0.10 per diluted share, in the prior year. This decline is attributable to the absence of non-recurring items that benefited the Q1 2025 results, specifically a gain on an equity investment and a legal expense recovery. The contrast between surging operating income and declining net income underscores the importance of distinguishing between operational performance and non-operational gains.

Cash Flow and Capital Allocation Signal Strategic Priorities

Regulatory and Trade Headwinds Loom